Mochida Pharmaceutical Co Ltd - Company Profile
Powered by 
All the data and insights you need on Mochida Pharmaceutical Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Mochida Pharmaceutical Co Ltd Strategy Report
- Understand Mochida Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Mochida Pharmaceutical Co Ltd (Mochida) develops, manufactures, and markets pharmaceutical and healthcare products including generics, specialty pharmaceuticals, and biosimilar products. The company's products are used for the treatment of arteriosclerosis obliterans, hyperlipidemia, pulmonary arterial hypertension, endometriosis, adenomyosis, thrombosis, acute pancreatitis, depression and depressive symptoms, chronic pain, cancer, chronic constipation, gout and hyperuricemia, ulcerative colitis, anticoagulant, antimycotic, and others. Its products under development are intended for the treatment of ulcerative colitis, insomnia, hyperlipidemia, articular cartilage lesion, and others. The company also offers contract manufacturing of pharmaceuticals. It operates state of art manufacturing facilities in Japan involved in technology transfers and the development of new drugs. Mochida is headquartered in Tokyo, Japan.
Headquarters
Japan
Address
1-7, Yotsuya, Shinjuku-Ku, Tokyo, 160-8515
Website
www.mochida.co.jp
Telephone
81 3 33587211
No of Employees
1,529
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4534 (TYO)
Revenue (2022)
$762.9M
-6.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-37.1%
(2022 vs 2021)
Market Cap*
$761.5M
Net Profit Margin (2022)
XYZ
-32.9%
(2022 vs 2021)
* As of and is in US$
Mochida Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Pharmaceutical | Contract Manufacturing | Lexapro |
| Lexapro- Antidepressant | Lialda | |
| Epadel- Hyperlipidemia and Arteriosclerosis Obliterans | Tramcet | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In October, the company and Shionogi & Co entered into a sales partnership agreement for the insomnia treatment drug, daridorexant in Japan. |
| 2023 | Regulatory Approval | In June, the company received marketing approval in Japan for Ulcerative Colitis Treatment. |
| 2023 | Regulatory Approval | In June, the company received marketing approval in Japan for cartilage repair material dMD-001. |
Competitor Comparison
| Key Parameters | Mochida Pharmaceutical Co Ltd | Astellas Pharma Inc | Daiichi Sankyo Co Ltd | Kyowa Kirin Co Ltd | Nippon Shinyaku Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Shinjuku-Ku | Chuo-Ku | Chuo-Ku | Chiyoda-Ku | Kyoto-Shi |
| State/Province | Tokyo | Tokyo | Tokyo | Tokyo | Kyoto |
| No. of Employees | 1,529 | 14,484 | 17,435 | 5,974 | 2,186 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Naoyuki Mochida | President; Director | Executive Board | 1999 | - |
| Keiichi Sagisaka | Director; Senior Executive Managing Director | Executive Board | 2013 | - |
| Chu Sakata | Director; Senior Executive Managing Director | Executive Board | 2013 | - |
| Kiyoshi Mizuguchi, Ph.D. | Executive Managing Director; Director | Executive Board | - | - |
| Naka Sakata | Executive Vice President - Assistant to the President; Director | Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward